In surprise decision, US approves muscular dystrophy drug - CNBC

1. In surprise decision, US approves muscular dystrophy drug  CNBC
2. Stocks To Watch With Stock Market At Record Highs Include Paycom Software  Investor's Business Daily
3. Sarepta’s surprise FDA approval for rare disease drug excites investors  MarketWatch
4. FDA OKs Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy  Medscape
5. Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal  Schaeffers Research
6. View full coverage on Google News

 
by via Top stories - Google News